Korea United Pharm Inc banner

Korea United Pharm Inc
KRX:033270

Watchlist Manager
Korea United Pharm Inc Logo
Korea United Pharm Inc
KRX:033270
Watchlist
Price: 18 500 KRW 0.16% Market Closed
Market Cap: ₩272.2B

Wall St Price Targets

Price Targets Summary
Korea United Pharm Inc

Wall Street analysts forecast Korea United Pharm Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Korea United Pharm Inc is 26 520 KRW with a low forecast of 26 260 KRW and a high forecast of 27 300 KRW.

Lowest Forecast
Price Target
26 260 KRW
42% Upside
Average Forecast
Price Target
26 520 KRW
43% Upside
Highest Forecast
Price Target
27 300 KRW
48% Upside
Korea United Pharm Inc Competitors:
Price Targets
PACB
Pacific Biosciences of California Inc
74% Upside

Revenue
Forecast

6% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
6% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 3 years is 6%.

Gross Profit
Forecast

6% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
6% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 3 years is 4%.

Operating Income
Forecast

7% / Year
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
7% / Year
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 3 years is 1%.

Pre-Tax Income
Forecast

7% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
7% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 3 years is 5%.

Net Income
Forecast

7% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
7% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 13 years, the compound annual growth rate for Net Income has been 7%. The projected CAGR for the next 3 years is 4%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is Korea United Pharm Inc's stock price target?
Price Target
26 520 KRW

According to Wall Street analysts, the average 1-year price target for Korea United Pharm Inc is 26 520 KRW with a low forecast of 26 260 KRW and a high forecast of 27 300 KRW.

What is the Revenue forecast for Korea United Pharm Inc?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 3 years is 6%.

What is the Gross Profit forecast for Korea United Pharm Inc?
Projected CAGR
4%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 3 years is 4%.

What is the Operating Income forecast for Korea United Pharm Inc?
Projected CAGR
1%

Over the last 13 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 3 years is 1%.

What is the Pre-Tax Income forecast for Korea United Pharm Inc?
Projected CAGR
5%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 3 years is 5%.

What is the Net Income forecast for Korea United Pharm Inc?
Projected CAGR
4%

Over the last 13 years, the compound annual growth rate for Net Income has been 7%. The projected CAGR for the next 3 years is 4%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett